Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeartSciencesHSCSW 18 Cash-to-Debt is 0.42 as of Apr. 2026, which is at its 10-year median of 0.42. GuruFocus rates HSCSW with a GF Score™ of 18/100. The stock has 10 warning signs investors should review. Among 841 Medical Devices & Instruments companies, HeartSciences ranks worse than 74.79% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HeartSciences's cash to debt ratio for the quarter that ended in Apr. 2026 was 0.42.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, HeartSciencescouldn't pay off its debt using the cash in hand for the quarter that ended in Apr. 2026.
The historical rank and industry rank for HeartSciences's Cash-to-Debt or its related term are showing as below:
HSCSW'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 0.42 Max: 5.61
Current: 0.42
During the past 7 years, HeartSciences's highest Cash to Debt Ratio was 5.61. The lowest was 0.15. And the median was 0.42.
HSCSW's Cash-to-Debt is ranked worse than 74.79% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs HSCSW: 0.42
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
HeartSciences Cash-to-Debt Related Terms
HeartSciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for HeartSciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HSCSW vs IRIX, ALRTF, ADGM: Cash-to-Debt Comparison
For the Medical Devices subindustry, HeartSciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeartSciences Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where HeartSciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeartSciences (HSCSW) has a Cash-to-Debt of 0.42 as of Apr. 2026. This is near median its historical median of 0.42. Over the past decade, HeartSciences' Cash-to-Debt has ranged from 0.15 to 5.61. According to the industry distribution chart, HeartSciences ranks #629 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 74.8%.
Is HeartSciences' Cash-to-Debt too high?
HeartSciences' current Cash-to-Debt of 0.42 is near median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 5.61. The Medical Devices & Instruments industry median Cash-to-Debt is 1.62. HeartSciences' value of 0.42 is 74.1% below this industry median. Based on the distribution chart, HeartSciences ranks #629 out of 841 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, HeartSciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does HeartSciences' Cash-to-Debt compare to IRIX and ALRTF?
According to the Medical Devices & Instruments industry distribution chart, HeartSciences ranks #629 out of 841 companies for Cash-to-Debt. This places HeartSciences in the lower half of its industry. The industry median Cash-to-Debt is 1.62. HeartSciences' value of 0.42 is 74.1% below this benchmark. Historically, HeartSciences' own Cash-to-Debt has ranged from 0.15 to 5.61 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 1.62, HeartSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.62, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeartSciences's current Cash-to-Debt of 0.42 is 74.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeartSciences's current Cash-to-Debt is 0.42, which is near median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartSciences stock overvalued right now?
HeartSciences (HSCSW) has a current Cash-to-Debt of 0.42. The current Cash-to-Debt is 0.42, which is near median its 10-year median of 0.42 and 74.1% below the Medical Devices & Instruments industry median of 1.62. HeartSciences' overall GF Score™ is 18/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For HeartSciences (HSCSW), the current Cash-to-Debt is 0.42 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
18GF Score
Get the complete analysis for HSCSW
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSCSW has been successfully added to your 
